Regulation & law · 11/08/2026

DEA Proposes Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV to Schedule V

The Drug Enforcement Administration is proposing to reclassify suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V under the Controlled Substances Act, which would impose stricter regulatory controls and penalties on those who handle these substances.